Lexington, MA-based Cubist Pharmaceuticals has bought out Astellas' rights to ceftolozane, putting up $25 million in cash for an antibiotic that has demonstrated some promising outcomes in clinical studies.
Analysts at GlobalData took a quarterly snapshot of the R&D expenses for a big batch of mid-cap biotechs and concluded that rising research costs were eroding corporate profitability. And they pinned the blame squarely on the pricey hunt for new cancer drugs.
Cubist Pharmaceuticals has stepped up with an option to buy out San Francisco-based Adynxx once it wraps up a mid-stage study of its lead drug for acute and chronic pain.
The drug discovery team at Heptares Therapeutics landed in San Francisco today with news of yet another development pact with a well-known biopharma player. This time its Boston, MA-based Cubist Pharmaceuticals which has jumped on the Heptares platform to find new drugs targeting G-protein coupled receptors.
Five years ago, when Chuck Magness and Shawn Iadonato completed the sale of Illumigen Biosciences to Cubist, the two were back at work on their new Seattle-based startup the very next day. Since then, they've been building a different kind of biotech, scooping up as much non-dilutive grant money as possible and looking to a nontraditional set of investors to fund the development of key assets.
Forma Therapeutics has nabbed an $815 million deal--$65 million of that in an upfront payment and the rest in pre-commercial milestones--to direct its growing drug discovery engine to new small
With its share price breaking through to a 52-week high, Cubist Pharmaceuticals ( $CBST ) has decided to beef up its pipeline of acute care products with a deal to buy Adolor Pharmaceuticals for $190
Cubist Pharmaceuticals isn't giving up on its drug against diarrhea caused by C. difficile. After saying in June it wasn't sure whether to continue development of the drug, the Lexington, MA-based
While Cubist Pharmaceuticals ( $CBST ) is mulling over whether to advance its antibiotic against C. difficile infections into late-stage development, an analyst says the developer might not pursue the
The market buzz about a potential Cubist Pharmaceuticals ( $CBST ) buyout grew on Monday with new rumors that Shire, fresh off its acquisition of Advanced BioHealing, was plotting a $2 billion offer